Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

17.40 +0.48 (+2.84%)

Streaming Delayed Price Updated: 11:40 AM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

January 07, 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

Via MarketBeat

Peering Into Intellia Therapeutics's Recent Short Interest ↗

December 24, 2024

Via Benzinga

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗

November 26, 2024

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Via Benzinga

Topics Artificial Intelligence

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? ↗

November 22, 2024

Via The Motley Fool

9 Analysts Have This To Say About Intellia Therapeutics ↗

November 11, 2024

Via Benzinga

A Glimpse of Intellia Therapeutics's Earnings Potential ↗

November 06, 2024

Via Benzinga

Looking Into Intellia Therapeutics's Recent Short Interest ↗

October 29, 2024

Via Benzinga

7 Analysts Have This To Say About Intellia Therapeutics ↗

October 25, 2024

Via Benzinga

From GLD To TSLA: Unlocking Today’s Best Trading Opportunities ↗

November 18, 2024

The week kicks off amidst significant market movements shaped by geopolitical and policy developments.

Via Talk Markets

Topics Stocks / Equities

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗

November 18, 2024

Via Benzinga

3 Fast-Growing Stocks Analysts See Doubling in Price

November 11, 2024

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

Via MarketBeat

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? ↗

November 06, 2024

There's nothing bearish at all about what it reported recently.

Via The Motley Fool

A Closer Look at Intellia Therapeutics's Options Market Dynamics ↗

October 24, 2024

Via Benzinga

3 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 24, 2024

Via Benzinga

Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts ↗

September 11, 2024

Via Benzinga

This Beaten-Down Stock Could Soar by 354%, According to Wall Street ↗

November 04, 2024

Maybe the Street is a bit too optimistic on this one.

Via The Motley Fool

12 High-Growth Stocks That Could Deliver Parabolic Returns ↗

October 28, 2024

These 12 innovative companies could deliver exponential returns over the next quarter century.

Via The Motley Fool

Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

October 24, 2024

The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36.

Via Benzinga

Topics Stocks

Why Intellia Therapeutics Stock Plummeted by 20% Today ↗

October 24, 2024

Seemingly encouraging results from the lab were met with some notable skepticism.

Via The Motley Fool

Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday? ↗

October 24, 2024

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

Via Benzinga

Expert Ratings For Intellia Therapeutics ↗

August 12, 2024

Via Benzinga

This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street ↗

October 17, 2024

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.

Via The Motley Fool

2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street ↗

October 09, 2024

These stocks haven't performed well this year.

Via The Motley Fool

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk ↗

September 29, 2024

The Ark Invest portfolio is known for taking aggressive bets.

Via The Motley Fool

3 Gene Editing Stocks with Potential to Transform Medicine ↗

August 09, 2024

Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks.

Via InvestorPlace

NTLA Stock Earnings: Intellia Therapeutics Misses EPS, Misses Revenue for Q2 2024 ↗

August 08, 2024

NTLA stock results show that Intellia Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

August 01, 2024

Via The Motley Fool

7 Biotech Stocks to Keep on Your Clinical Radar ↗

July 23, 2024

Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.

Via InvestorPlace

3 Gene Editing Stocks That Could Grow Your Wealth ↗

July 17, 2024

Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks.

Via InvestorPlace

3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition ↗

July 17, 2024

Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.